OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push 
Google to Move All Pixel Production Out of China by 2027 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI 
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Add as a preferred source on Google
The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay $235.5 million to GlaxoSmithKline Plc for selling a generic version of a heart drug, covered by the latter's patent.
In a 2-1 decision, the appeals court found “substantial evidence” that Teva induced doctors to prescribe its generic tablets.
Israeli drugmaker Teva plans to appeal and introduce additional defenses that it neither infringed nor induced doctors to infringe Glaxo’s patent.
The case arose after Teva began selling a generic version of Coreg, which Glaxo had won U.S. approval for, in 2007.
Coreg treats hypertension, left ventricular dysfunction after a heart attack, and congestive heart failure.
In 2017, a Delaware jury ordered the to pay $234.1 million for lost profit plus $1.4 million in royalties.
US District Judge Leonard Stark overturned the verdict due to other factors that could have caused doctors to prescribe Coreg.
But Circuit Judge Pauline Newman said Teva's promotional materials, product catalogs, the FDA labels, press releases, and witness testimony supported allegations of “induced infringement.”
